Kinetic assessment of breast tumors using high spatial resolution signal enhancement ratio (SER) imaging.
The goal of this study was to investigate the relationship between an empirical contrast kinetic parameter, the signal enhancement ratio (SER), for three-timepoint, high spatial resolution contrast-enhanced (CE) MRI, and a commonly analyzed pharmacokinetic parameter, kep, using dynamic high temporal resolution CE-MRI. Computer simulation was performed to investigate: 1) the relationship between the SER and the contrast agent concentration ratio (CACR) of two postcontrast timepoints (tp1 and tp2); 2) the relationship between the CACR and the redistribution rate constant (kep) based on a two-compartment pharmacokinetic model; and 3) the sensitivity of the relationship between the SER and kep to native tissue T1 relaxation time, T10, and to errors in an assumed vascular input function. The relationship between SER and kep was verified experimentally using a mouse model of breast cancer. The results showed that a monotonic mathematical relationship between SER and kep could be established if the acquisition parameters and the two postinjection timepoints of SER, tp1, tp2, were appropriately chosen. The in vivo study demonstrated a close correlation between SER and kep on a pixel-by-pixel basis (Spearman rank correlation coefficient=0.87+/-0.03). The SER is easy to calculate and may have a unique role in breast tissue characterization.
Li
Ka-Loh
KL
Department of Radiology, University of California San Francisco, San Francisco, California 94107-0946, USA. ka-loh.li@radiology.ucsf.edu
Henry
Roland G
RG
Wilmes
Lisa J
LJ
Gibbs
Jessica
J
Zhu
Xiaoping
X
Lu
Ying
Y
Hylton
Nola M
NM
D000465:Algorithms; D000818:Animals; D001940:Breast / Q000098:blood supply / Q000378:metabolism; D001943:Breast Neoplasms / Q000175:diagnosis*; D045744:Cell Line, Tumor; D003198:Computer Simulation; D003287:Contrast Media / Q000493:pharmacokinetics; D004195:Disease Models, Animal; D005260:Female; D019786:Gadolinium DTPA / Q000097:blood / Q000493:pharmacokinetics; D006801:Humans; D007089:Image Enhancement / Q000379:methods*; D007091:Image Processing, Computer-Assisted / Q000379:methods; D008279:Magnetic Resonance Imaging / Q000379:methods*; D008325:Mammary Neoplasms, Experimental / Q000175:diagnosis / Q000188:drug therapy; D051379:Mice; D008819:Mice, Nude; D008954:Models, Biological; D020794:Receptor Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D013997:Time Factors; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
D003287:Contrast Media; D042461:Vascular Endothelial Growth Factor A; D020794:Receptor Protein-Tyrosine Kinases; D019786:Gadolinium DTPA